Can-Fite Starts Preclinical Studies Required By FDA, EMA For Two Lead Drug Candidates Registration FilingBenzinga • 04/20/21
Can-Fite Initiates Preclinical Studies Required by FDA and EMA for the Registration of its Two Lead Drug CandidatesBusiness Wire • 04/20/21
Can-Fite Says Cannabinoid-Based Therapies Stop Liver Cancer Growth, Preclinical Studies ShowBenzinga • 04/05/21
Can-Fite: Cannabis Compound Inhibits Liver Cancer Growth in Preclinical StudiesBusiness Wire • 04/05/21
Can-Fite: Summary of Existing Out-licensing Deals with Potential Milestone Payments of up to approximately $130 millionBusiness Wire • 03/30/21
Can-Fite Reports 2020 Financial Results & Provides Clinical Development UpdateBusiness Wire • 03/25/21
New Positive Data from Can-Fite's Liver Cancer Phase II Clinical Study with NamodenosonBusiness Wire • 02/22/21
Can-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical StudiesBusiness Wire • 02/01/21
Can-Fite's NASH Indication Highlighted in Webinar by KOL Dr. Harrison: “Namodenoson May Have Big Impact on NASH”Business Wire • 01/28/21
Piclidenoson From Can-Fite Biopharma Shows New, Promising Developments For Psoriasis TreatmentBenzinga • 01/19/21
Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal—CancersBusiness Wire • 01/08/21
Can-Fite Receives Israel Ministry of Health Approval to Conduct Research with Cannabinoids in Cancer, Inflammation and Obesity at the Company Discovery LabsBusiness Wire • 12/15/20
Can-Fite BioPharma Ltd. (CANF) CEO Pnina Fishman on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/30/20
Can-Fite Reports Third Quarter 2020 Financial Results & Provides Clinical UpdateBusiness Wire • 11/30/20
Can-Fite's Namodenoson Abstract Selected as ‘Best of The Liver Meeting' in the NASH Category of the American Association of Liver Diseases (AASLD)Business Wire • 11/24/20